Baicalein (5,6,7-trihydroxyflavone) is a flavonoid derived from the root of Scutellaria baicalensis, a traditional Chinese medicine used for hundreds of years. This flavonoid demonstrates a variety of biological activities, such as antibacterial, antiinflammatory, antioxidant, antitumor, antiproliferative, anticoagulant, and vascular-protective effects. 1, 2) Baicalein is also an inhibitor of reverse transcriptase of the human immunodeficiency virus (HIV), interferes with the RNA replication of HIV, and induces apoptosis in infected cells in vitro.
Baicalein is also an inhibitor of reverse transcriptase of the human immunodeficiency virus (HIV), interferes with the RNA replication of HIV, and induces apoptosis in infected cells in vitro. 3) Baicalein is the most potent inhibitor of the human cytomegalovirus (HCMV), displaying an IC 50 value of 0.4Ϯ0.04 mM in the colorimetric assay and 1.2Ϯ0.8 mM in the titer reduction assay. It also significantly reduces the levels of early and late proteins of HCMV, as well as viral DNA synthesis. 4) Influenza, one of the major pandemic diseases worldwide, represents a grave threat to human health. At present, only two types of chemical drug are used clinically in the treatment of influenza. One type is the M2 proton channel blockers (amantadine and rimantadine), and the other is neuraminidase inhibitors (zanamivir and oseltamivir). However, resistance to these drugs has been reported. [5] [6] [7] [8] Furthermore, the high price and lack of a sufficient supply prevent oseltamivir (Tamiflu) from being widely used in developing countries. Traditional Chinese medicine, which is widespread in nature with good efficacy, is beginning to play a more important role in this area.
It has been reported that baicalein demonstrates inhibitory effects on viruses and that more than 90% of baicalein is rapidly metabolized into baicalin, which is transported to the mesenteric blood when perfused through the rat jejunum. 9, 10) However, the mechanism of its antiviral effect is unknown. Here, we report for the first time that baicalein has an inhibitory effect on the influenza virus A/FM1/1/47(H1N1) in vivo and that this effect is mainly due to its metabolite baicalin in serum.
MATERIALS AND METHODS
Reagents Baicalein was a gift from Prof. Qinglong Guo of the Deptartment of Physiology, China Pharmaceutical University. It was dissolved in 0.5% sodium carboxymethyl cellulose (CMC) for in vivo experiments and in dimethyl sulfoxide (DMSO) for in vitro tests. Ribavirin injection was obtained from the China Pharmaceutical University Pharmaceutical Co., Ltd., Nanjing, China. Reference samples of baicalein and baicalin used in HPLC analysis were obtained from the National Institution for the Control of Pharmaceutical and Biological Products, China. Methanol, acetonitrile, and phosphoric acid (HPLC grade) were purchased from Sinopharm Chemical Reagent Co., Ltd., Shanghai, China.
Virus and Cells
The influenza A/FM1/1/47(H1N1) virus used in this study was preserved in the Department of Microbiology, School of Life Science and Technology, China Pharmaceutical University. The virus was grown in the allantoic cavity of 10-d-old embryonated hen eggs at 37°C for 2 d.
11) The allantoic fluid was harvested and filtered with a 0.22-mm cellulose acetate membrane. The filtered liquid was stored in small aliquots at Ϫ70°C until further use.
Madin-Darby canine kidney (MDCK) cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal calf serum (FCS). The cells were incubated in a humidified atmosphere of 5% CO 2 at 37°C.
Animals Ninety-six female BALB/c mice (18-22 g) and 10 Sprague-Dowley (SD) rats were obtained from the Laboratory Animal Center, Nanjing Medical University, China, and treated according to the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health.
Antiviral Effects of Baicalein in Vivo After a 2-d acclimation period, the mice were slightly anesthetized by the inhalation of diethyl ether and intranasally infected with 8ϫ MLD 50 of mouse-adapted influenza A/FM1/1/47(H1N1) virus in 100 ml of phosphate buffered saline (PBS). The mice were treated with various doses of baicalein solution (240, 480, 960 mg/kg/d) by oral gavage twice daily for 4 d beginning 24 h after virus inoculation. Ribavirin (400 mg/kg/d) or sterile sodium chloride (100 ml) was given as a positive control or placebo control, respectively. All doses were determined in advance in toxicity experiments. Normal controls were treated with sodium chloride. Ten animals per group were observed for 14 d for clinical signs of infection or death.
An additional 6 mice per group were used to assess lung infection parameters on day 5 of infection with the influenza virus. Mice were weighed and killed, and then the lungs were removed and weighed. The lung index and lung index inhibition were calculated as:
where A is lung weight, B is body weight, C is mean lung index of the placebo control group, and D is mean lung index of the drug-treated group.
Lung consolidation scores ranging from 0 (normal appearance) to 4 (100% of the lung exhibiting a plum color) were assigned. After being fixed in 10% formalin and embedded in paraffin, four lungs per group were sectioned for histologic examination. Pathologic changes were evaluated based on the following aspects: hyperemia and bleeding of the lungs; leukopedesis; bronchiole epithelium cell necrosis; exudate of lung; alveolus interstitial pneumonia; and lung abscess.
The remnant lungs were homogenized in PBS to give a 10% (w/v) suspension, and the homogenate was centrifuged at 2000ϫg for 10 min. The supernatant was serially diluted and inoculated into 10-d-old embryonated hen eggs. Virus titers in the lungs were calculated using the method of Reed and Muench 12) and egg infective dose (EID) expressed as mean log 10 EID 50 /mlϮS.D.
Preparation of Medicine Serum Ten SD rats were used in this experiment. Six rats were orally administered a baicalein solution at a dose of 500 mg/kg once daily for 5 d. The other 4 rats were treated with saline as controls. On day 5, after 2.5 h of treatment with baicalein, the rats were anesthetized with an intraperitoneal injection of 10% (m/v) amobarbital sodium at a dose of 500 mg/kg, and blood was collected under sterile conditions from the main ventral artery. After standing at 4°C for 30 min, the serum was obtained by centrifugation at 3000ϫg for 20 min and stored in small aliquots at Ϫ20°C.
13)
HPLC was used for quantitative analysis of baicalein and its metabolite baicalin in the serum. The LC-2010 Shimadzu HPLC system was employed with a Class VP workstation for data collection. Liquid chromatographic separation was achieved using a Lichrospher C 18 analytical column (6.0 mmϫ150 mm, 5 mm) connected to a C 18 guard column (Hanbon Science & Technology Co., Ltd., Jiangsu, China). Reference substances of baicalein and baicalin were dissolved in methanol to concentrations of 196 mg/ml and 19.8 mg/ml, respectively, for use as internal standards. To prepare for HPLC analysis, 400 ml of methanol-acetonitrile (1 : 1, v/v) and 100 ml of 0.4% phosphoric acid were added to a 200-ml serum sample. After vortex mixing for 3 min, the mixture was centrifuged for 10 min at 12000ϫg. Six hundred microliters of the upper layer was obtained, evaporated under N 2 , and reconstituted with 200 ml of the mobile phase prior to HPLC analysis. Blank serum and blank serum with 20 ml of the internal standards were prepared in parallel as controls. 14, 15) The mobile phase consisted of methanol-0.2% phosphoric acid (48 : 52, v/v) at a constant flow rate of 1.0 ml/min. The column temperature and the detection wavelength were set at 30°C and 275 nm, respectively. The preparations were analyzed both qualitatively and quantitatively by comparisons of retention times and analyzed peak areas with those of the internal standards.
Antiviral Effects of Medicine Serum in Vitro Antiviral activities of medicine serum were measured in the plaque inhibition assay. MDCK cells (1ϫ10 5 cells/ml) were cultured in 24-well plastic plates for 24 h and inoculated with 100 plaque forming units (PFU) per well of influenza A/FM1/ 1/47(H1N1) virus. After 60 min for virus absorption, the solution was removed and replaced with 1 ml of overlay medium (DMEM medium containing 1% carboxymethyl cellulose, without serum) containing different concentrations of medicine serum. The final concentrations of baicalin in the overlay medium were 0.5 mg/ml, 1 mg/ml, and 2 mg/ml. After incubation at 37°C for 3 d, the solution was removed and the cells were fixed with 10% formaldehyde solution for 60 min at room temperature. Then the cells were stained with 0.5% (w/v) crystal violet solution for 15 min, and the number of plaques was counted for each well.
Cytopathic Effect Assay To examine whether baicalin can inhibit the cytopathic effect (CPE) of cells infected by influenza A/FM1/1/47(H1N1) virus, a 96-well tissue culture plate was seeded with 100 ml of 1ϫ10 5 cells/ml in DMEM with 10% FBS. After cells were incubated for 18-24 h at 37°C, the solution was removed and the cells were infected with 100 PFU per well of influenza A/FM1/1/47(H1N1) virus at 37°C for 1 h. The viral inocula were removed and replaced with growth medium (DMEM medium without serum) containing different concentrations of medicine serum. The final concentrations of baicalin in the growth medium were 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, and 3 mg/ml. Each treatment was performed in quadruplicate. After incubation for 3 d at 37°C, the cells were fixed with 100 ml of 10% formaldehyde for 1 h at room temperature. After removal of the formaldehyde, the cells were stained with 0.5% (w/v) crystal violet solution for 15 min at room temperature. The plate was washed and dried, and the intensity of crystal violet staining for each well was measured at 570 nm. The IC 50 value of baicalin was calculated from the absorbance values. 16) Statistical Analysis Data from the in vivo studies are presented as meanϮS.D. Comparisons were made between drug-treated and placebo groups. Differences in the mean day to death, lung consolidation scores, and lung virus titers were analyzed using the two-tailed Mann-Whitney U-test. The probability of survival was estimated with the Kaplan-Meier method, and survival estimates were compared using the log-rank test. 17) 
RESULTS

Antiviral Effects of Baicalein in Vivo
Influenza viral infection leads to high mortality, lung virus titers, and pneumonia. 18) Therefore the efficacy of treatment was evaluated on the basis of survival rate, mean day to death, lung virus titers, and lung parameters including lung consolidation and the inhibition of the lung index. The results showed that baicalein displayed a protective effect on mice infected with influenza A/FM1/1/47(H1N1) virus (Table 1) . Oral gavage with all doses of baicalein (240, 480, 960 mg/kg/d) resulted in protection from death and statistically significant prolonged survival time of mice. A survival rate of 50% was obtained even at the lowest dose of 240 mg/kg/d, while all the placebo control mice died. Compared with the other two doses, treatment with baicalein at the dose of 960 mg/kg/d had the most effect on life protection with a survival rate of 70% and the mean day to death of 12.4Ϯ2.6 d. Furthermore, in the 960 mg/kg/d group, mortality occurred on day 8 after infection, which was 3 d later than in the placebo group, 2 d later than in the 240 mg/kg/d group, and 1 d later than in the 240 mg/kg/d group (Fig. 1) .
Lung parameter data showed that treatment with baicalein provided a dose-dependent protective effect from viral pneumonia ( Table 1) . Inhibition of the lung index was detected at 26%, 30%, and 35% with the doses of 240, 480, and 960 mg/kg/d, respectively. Stronger inhibition of the lung index (35%) and less lung consolidation (1.2Ϯ0.75) were observed in the mice treated with baicalein 960 mg/kg/d than in those treated with ribavirin (32%; 1.3Ϯ0.52). Meanwhile, virus replication was reduced in all treatment groups. The lowest virus titer detected was 3.8Ϯ0.8 in 960 mg/kg/d group. The results of the histologic examination were consistent with the lung parameter data (Fig. 2) . Protection from bronchitis and interstitial pneumonia was found in all groups treated with baicalein, and the degrees of protection were different depending on the baicalein dose. The mice were killed 3 d after infection. The lungs were removed and rinsed with sterile PBS. After fixing in 10% formalin and embedding with paraffin, the lungs were sectioned for histologic examinations. Pathologic changes were evaluated based on hyperemia and bleeding of lungs, leukopedesis, bronchiole epithelium cell necrosis, exudate of lung, alveolus interstitial pneumonia, and lung abscess.
Determination of Baicalin in Serum
of baicalein and its metabolite in the serum of rats treated with baicalein (500 mg/kg) were analyzed using HPLC 2.5 h after treatment on day 5 (Fig. 3) . The retention times of baicalein and baicalin were 34.2 min and 10.6 min, respectively. Baicalin at the concentration of 17.0 mg/ml was detected in the serum of treated rats, while baicalein was detected at the concentration of 0.8 mg/ml, suggesting that the majority of baicalein had been metabolized into baicalin, and the amount of baicalein remaining was extremely small. Antiviral Effects of Medicine Serum in Vitro MDCK cells were infected with influenza A/FM1/1/47(H1N1) virus and incubated in overlay medium with medicine serum containing various concentrations of baicalin for 72 h. It was shown that baicalin inhibited influenza virus replication in a dose-dependent manner (Fig. 4A) . At the concentrations of 1 mg/ml and 2 mg/ml, baicalin showed significant inhibitory effect. At 0.5 mg/ml, baicalin showed a slight inhibitory effect. Therefore the concentration of baicalin that effectively reduced the plaque of influenza A/FM1/1/47(H1N1) virus was between 0.5 mg/ml and 1 mg/ml. The level of protection of MDCK cell monolayers provided by baicalin from viral CPE was measured using influenza A/FM1/1/47(H1N1) virus. The ratio of 100 PFU per well of virus was required to produce 90% CPE at 3 d post infection. After staining of the cell monolayers with crystal violet, four sets of absorbance values were averaged to generate a dose-response curve (Fig.  4B) . Absorbance values were proportional to the overall health of the cell monolayers, as demonstrated by the reduction in protection afforded by baicalin as the concentration decreased. Protection of the monolayers from the CPE induced by influenza A/FM1/1/47(H1N1) virus was observed at baicalin concentrations from 1 to 3 mg/ml. The IC 50 value of baicalin was calculated as 1.2 mg/ml from the inhibition curve.
DISCUSSION
In this paper, the inhibitory activity of baicalein against influenza A/FM1/1/47(H1N1) virus in vivo was examined and its mechanism investigated. The oral administration of baicalein showed good effect against influenza A/FM1/1/ 47(H1N1) virus infection in mice, such as increasing survival rate, prolonging survival time, inhibiting lung consolidation, and reducing lung virus titers. Baicalin, with a glucose residue, was difficult to absorb. After oral administration, it was converted into baicalein by b-glucuronidase of intestinal bacteria and absorbed. When transported to the liver, baicalein was transformed into metabolites by UDP-glucuronosyltransferases (UGT) in liver microsomes and exerted activity, [19] [20] [21] including 7-O-glucuronide-6-methoxyl-5-hydroxyflavone, 6-O-glucuronide-5,7-dihydroxyflavone, and 7-O-glucuronide-5,6-dihydroxyflavone (baicalin) (Fig. 5) . Among them, baicalin was the main metabolite. This mechanism was similar to the activation of sennosides and saikosaponin. Sennosides present in Sennae folium are metabolized to rhein and rhein anthrone to produce a laxative action. [22] [23] [24] Saikosaponin extracted from the root of Bupleurum falcatum must be metabolized in the intestinal tract to exert antiinflammatory and antitumor activity. [25] [26] [27] According to our results, the serum of rats orally administered baicalein for 2.5 h exhibited an obvious inhibitory effect on the duplication of influenza A/FM1/1/47(H1N1) virus in MDCK cells. Since the amount of baicalein detected in the serum was too small to exert that effect and baicalin is the predominant metabolite of baicalein, it was reasonably concluded that baicalin plays an important role in antiinfluenza activity. From the data obtained, the IC 50 value of baicalin against the influenza virus in vitro was 1.2 mg/ml in the CPE assay, and baicalin also showed significant effects against the virus at the concentration of 2 mg/ml based on the plaque inhibition assay. According to previous studies, [28] [29] [30] the concentration of ribavirin which was effective in inhibiting the influenza virus in vitro was from 2.5 to 10 mg/ml. These suggest that there are similar antiviral effects between serum containing baicalin and ribavirin in vitro. The data also showed that baicalin at the plasma concentration of 17 mg/ml is sufficient to inhibit the duplication of influenza virus in vivo.
It was reported that the plasma concentration of baicalin reached a maximum 2.5 h after baicalein was absorbed with oral administration. 31) However, with the same administration of baicalin, about 10 h was required to reach the maximal plasma concentration, which is lower than with the oral administration of baicalein. Therefore we concluded that baicalein is more effective than baicalin in inhibiting the replication of influenza virus with oral administration, and it is more likely to be a potential antiinfluenza viral agent for clinical use.
The mechanism of the antiinfluenza viral activity of baicalin has not been revealed. Neuraminidase, a specific glycoprotein on the surface of the influenza virus, is essential for viral replication due to its role in facilitating the release of progeny virions from infected cells. 32) It is a valid drug target for the development of antiinfluenza therapeutics. In our initial neuraminidase inhibition assay, baicalin to some extent inhibited neuraminidase activity (data not shown). Our subsequent investigations will explore this effect. Furthermore, it was reported that baicalin significantly inhibits hepatitis B virus (HBV) and herpes simplex virus-1 (HSV)-1 in vitro 33, 34) and shows some effect against HIV. 35) It is reasonable to assume that baicalin possesses a common, nonspecific antiviral mechanism based on its inhibitory effects on a large number of viruses. We will also search for the mechanism through its modulation of the immune system in our future investigations.
